Trial reportInternational ophthalmology2025
Jueling Mingmu decoction combined with ranibizumab for retinal vein occlusion induced macular edema: A randomized controlled clinical trial.
Trial report in International ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Baicalin Protects ARPE-19 Cells Against BRVO-Related Hypoxic Injury by Preserving Mitochondrial Function and Inhibiting Ferroptosis.Antioxidants (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
BACKGROUND/
aimsTo investigate the efficacy of a combined treatment approach using Jueling Mingmu Decoction and ranibizumab in managing macular edema (ME) associated with retinal vein occlusion (RVO).
methodsThis prospective, randomized, controlled, outcome assessor-blinded superiority trial involved 111 patients with treatment-naïve RVO and ME, including 53 patients assigned to the ranibizumab monotherapy group and 58 to the combination therapy group. Participants were randomly assigned to receive either intravitreal injections of 0.5 mg ranibizumab alone (monotherapy group) or combined with daily consumption of Jueling Mingmu Decoction (combination group). Primary outcomes included the number of intravitreal injections administered over 48 weeks. Secondary outcomes included changes in best-corrected visual acuity (BCVA) and central subfield fovea thickness (CST).
results99 patients (89.2%) completed the 48-week follow-up, including 46 of 53 patients (86.8%) in the monotherapy group and 53 of 58 patients (91.4%) in the combination group. The monotherapy group received an average of 4.35 ± 1.73 injections, while the combination group received 4.64 ± 1.92 injections (P = 0.471), with no significant difference between the groups. BCVA improved significantly in both groups, with the combination group showing a greater improvement at 48 weeks in patients with branch RVO (BRVO) compared to the monotherapy group (P = 0.031). CST decreased significantly in both groups, with the combination group showing a significantly lower CST at 36 weeks in BRVO patients (P = 0.018). No significant differences were observed between the groups for central retinal vein occlusion (CRVO) patients.
conclusionThe combination of Jueling Mingmu Decoction and ranibizumab appears to be a potentially effective treatment for improving visual and anatomical outcomes in RVO-related ME, especially in BRVO patients. However, it does not significantly reduce the number of required intravitreal injections compared to monotherapy. Further studies are needed to confirm these findings and explore the long-term efficacy and safety of this treatment approach.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.